



Autolus Therapeutics PLC 2023 Annual General Meeting Results

On June 30, 2023, Autolus Therapeutics plc (the “Company”) held its 2023 annual general meeting of shareholders (the “AGM”).

At the AGM, the holders of 124,868,259 votes of the Company’s ordinary shares, which may be represented by American Depositary Shares (“ADSs”), were represented in person or by proxy, constituting a quorum. Voting at the AGM was conducted by way of a poll, and each ordinary share, which may be represented by ADSs, issued and outstanding as of the close of business on the record date was entitled to one (1) vote on each resolution at the AGM.

The following are the voting results for the proposals considered and voted upon at the AGM, each of which was an ordinary resolution requiring a simple majority:

Proposal	For	Against	Vote Withheld
To receive and adopt the Company’s accounts for the financial year ended 31 December 2022 and the associated reports of the Directors and auditors	124,804,903	40,397	31,354
To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy set out on pages 21 to 32 (inclusive) of the Directors’ remuneration report)	113,796,036	10,948,296	132,322
To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of the AGM until the conclusion of the AGM of the Company to be held in 2024 and to authorise the Directors to determine the auditors’ remuneration	124,834,545	33,714	8,395
To re-elect Mr. J Berriman as a Director	118,596,299	6,090,871	189,484
To re-elect Dr. K Dhingra as a Director	116,109,200	8,577,975	189,479
To re-elect Mr. J Johnson as a Director	117,783,105	6,904,065	189,484

Based on the foregoing votes, the shareholders approved all of the proposals. The results were in line with the recommendations made by the Company’s board of directors.